I specialize in the care of children with lymphomas, especially cancers that have returned despite prior treatment. I also conduct clinical research to design and assess investigational therapies — particularly antibodies and new targeted agents that take aim at the molecular signaling pathways that drive cancer growth — for children with all types of cancer.
I am a co-founder of POETIC (Pediatric Oncology Experimental Therapeutics Investigator Consortium), a collaboration between multiple centers around the country whose mission is the development of biologically targeted therapies for cancers that have recurred in children. We started POETIC in February 2003 to increase patients’ access to promising new agents in clinical trials. I serve as Director of the POETIC Coordinating Center at Memorial Sloan Kettering, the only POETIC center in New York City.
I have a background in molecular pharmacology and therapeutics laboratory research, especially studies of the molecular mechanisms of drug resistance. I believe that understanding the fundamental biology of cancer is vital to our ability to improve cancer treatment. The work we’ve done in the laboratory and its translation to improve the treatment of lymphoma is now being applied to the care of children with other types of cancer. This is very satisfying for me, and serves as a tribute to the patients we’ve treated. Research enables us to provide options when no others are available and gives parents hope.
I am involved on the national level in the Children’s Oncology Group, where I serve as Chairperson of the Hodgkin’s Biology Committee and Vice Chair of the Hodgkin’s Disease Committee. I also teach fellows and have mentored several who have gone on to start their own research programs, and I am very proud to help them start their careers. I have received several awards for my work, including being named a Diamond Member of the International Association of Pediatricians and The Leading Physicians of the World in 2010.
It is very gratifying when I see patients conquer cancer and go on to do well. I understand how critical research is to advancing the treatment of cancer, and it is rewarding to know that the investigations I am leading may save the life of a child.
- Clinical Expertise: Pediatric Oncology; Hodgkin and Non-Hodgkin Lymphoma; Leukemias; New Investigational Agents; Drug Resistance
- Languages Spoken: English
- Education: MD, Duke University School of Medicine
- Residencies: Duke University Medical Center
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Pediatrics; Pediatric Hematology-Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Tanya M. Trippett
- A Phase I Study of MPDL3280A (Atezolizumab) in Children and Young Adults with Persistent Solid Tumors
- A Phase I Study of SGN-CD19A in Children and Adults with Persistent B-Cell Acute Lymphoblastic Leukemia or Aggressive Non-Hodgkin Lymphoma
- A Phase I/II Clinical Study of Vorinostat Plus Etoposide in Pediatric Patients with Refractory Solid Tumors
- A Phase I/II Study of Brentuximab (SGN-35) in Pediatric Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma or Hodgkin Lymphoma
- A Phase II Study of Cyclophosphamide, Topotecan, and Bevacizumab in Patients with Relapsed or Refractory Ewing's Sarcoma and Neuroblastoma
Clinical Trials Co-Investigated by Tanya M. Trippett
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more